Back to top
more

Zynerba Pharmaceuticals, Inc. (ZYNE)

(Delayed Data from NSDQ)

$11.45 USD

11.45
2,372,198

+0.35 (3.15%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.45 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $10.01, marking a +1.11% move from the previous day.

Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $8.23, marking a -0.84% move from the previous day.

Will Zynerba Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.

Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Will Zynerba Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.

Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3

Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.

Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

      Madeleine Johnson headshot

      Zynerba Pharma (ZYNE) Stock Soars on Positive Cannabis-Based Drug Results

      On Thursday, shares of clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) are soaring, up nearly 54% in afternoon trading after it announced positive results in a mid-stage study of its cannabis-derived gel treatment.

        Are Options Traders Betting on a Big Move in Zynerba Pharmaceuticals (ZYNE) Stock?

        Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

          Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

          Options traders are pricing in a big move for Zynerba Pharmaceuticals (ZYNE) shares as it has huge implied volatility.

            Arpita Dutt headshot

            Play the Marijuana Rush as First Marijuana-Focused ETF Launches

            The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.

              Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%

              Agile Therapeutics, Inc. (AGRX) moved big last session, as its shares rose almost 14% on the day.

                Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?

                The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.

                  DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?

                  DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.

                    Zynerba Pharmaceuticals (ZYNE) Shares March Higher, Can It Continue?

                    Zynerba Pharmaceuticals, Inc. (ZYNE) has been on the move lately as the stock has risen by 19.8% in the past four weeks, and it is currently trading well above its 20-Day SMA

                      Can Penumbra (PEN) Spring a Surprise this Earnings Season?

                      Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.

                        Patterson Companies (PDCO) Q3 Earnings: What's in Store?

                        Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.

                          Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?

                          Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.

                            Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 9.5%

                            Zynerba Pharmaceuticals, Inc. (ZYNE) moved big last session, as its shares jumped over 9% on the day.